Cargando…

Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial

Aim: Sex-specific analyses of direct head-to-head comparisons between newer P2Y(12) inhibitors are limited. This study was conducted to assess the efficacy and safety of ticagrelor versus prasugrel in women and men with acute coronary syndromes (ACS) planned for an invasive strategy. Methods: This p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gewalt, Senta, Lahu, Shqipdona, Ndrepepa, Gjin, Pellegrini, Costanza, Bernlochner, Isabell, Neumann, Franz-Josef, Menichelli, Maurizio, Morath, Tanja, Witzenbichler, Bernhard, Wöhrle, Jochen, Hoppe, Katharina, Richardt, Gert, Laugwitz, Karl-Ludwig, Schunkert, Heribert, Kastrati, Adnan, Schüpke, Stefanie, Mayer, Katharina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135658/ https://www.ncbi.nlm.nih.gov/pubmed/33867409 http://dx.doi.org/10.5551/jat.62776

Ejemplares similares

Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial
por: Behnes, Michael, et al.
Publicado: (2022)

Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes ‐ A Post‐hoc Analysis of the ISAR‐REACT 5 Trial
por: Lahu, Shqipdona, et al.
Publicado: (2022)

Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes
por: Ndrepepa, Gjin, et al.
Publicado: (2021)

Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
por: Koch, Tobias, et al.
Publicado: (2023)

High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
por: Mayer, Katharina, et al.
Publicado: (2023)

Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes
por: Ndrepepa, Gjin, et al.
Publicado: (2021)

Association of De Ritis Ratio with Prognosis in Patients with Coronary Artery Disease and Aminotransferase Activity within and outside the Healthy Values of Reference Range
por: Ndrepepa, Gjin, et al.
Publicado: (2023)

Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y(12) Inhibitor Thereafter
por: Lahu, Shqipdona, et al.
Publicado: (2022)

Time-of-day at symptom onset was not associated with infarct size and long-term prognosis in patients with ST-segment elevation myocardial infarction
por: Sager, Hendrik B., et al.
Publicado: (2019)

Periprocedural myocardial injury according to optical characteristics of neointima and treatment modality of in-stent restenosis
por: Nano, Nejva, et al.
Publicado: (2022)

Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis
por: Lohaus, Raphaela, et al.
Publicado: (2016)

Long‐Term Ticagrelor Versus Prasugrel Pharmacodynamics in Patients With ST‐Segment–Elevation Myocardial Infarction
por: Cassese, Salvatore, et al.
Publicado: (2020)

Coronary No-Reflow after Primary Percutaneous Coronary Intervention—Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy
por: Ndrepepa, Gjin, et al.
Publicado: (2023)

Association of In‐Hospital Hemoglobin Drop With Decreased Myocardial Salvage and Increased Long‐Term Mortality in Patients With Acute ST‐Segment–Elevation Myocardial Infarction
por: Dutsch, Alexander, et al.
Publicado: (2022)

ISAR-REACT 5 — What have we learned?
por: Kubica, Jacek, et al.
Publicado: (2019)

ISAR‐PEBIS (Paclitaxel‐Eluting Balloon Versus Conventional Balloon Angioplasty for In‐Stent Restenosis of Superficial Femoral Artery): A Randomized Trial
por: Ott, Ilka, et al.
Publicado: (2017)

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
por: Alexopoulos, Dimitrios, et al.
Publicado: (2013)

Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients
por: Gager, Gloria M., et al.
Publicado: (2020)

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2022)

Antithrombotic therapy with or without clopidogrel after transcatheter aortic valve replacement. A meta-analysis of randomized controlled trials
por: Pellegrini, Costanza, et al.
Publicado: (2020)

Tolvaptan in the very elderly with acute decompensated heart failure-a therapeutic option worth of consideration
por: Ndrepepa, Gjin
Publicado: (2017)

Atherosclerosis & ischaemic heart disease: Here to stay or gone tomorrow
por: Ndrepepa, Gjin
Publicado: (2017)

Epicardial adipose tissue: An anatomic component of obesity & metabolic syndrome in close proximity to myocardium & coronary arteries
por: Ndrepepa, Gjin
Publicado: (2020)

Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study
por: Alexopoulos, Dimitrios, et al.
Publicado: (2015)

Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study
por: Winter, Max-Paul, et al.
Publicado: (2019)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
por: Dai, Lulu, et al.
Publicado: (2022)

Real‐World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
por: Yildirim, Mustafa, et al.
Publicado: (2023)

Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus: Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents (ISAR-TEST 5) trial
por: Koch, Tobias, et al.
Publicado: (2021)

Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
por: Wiebe, Jens, et al.
Publicado: (2021)

Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography
por: Olechowski, Bartosz, et al.
Publicado: (2016)

Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis
por: Wen, Mingxiang, et al.
Publicado: (2020)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Publicado: (2019)

The Effect of Ticagrelor on Endothelial Function Compared to Prasugrel, Clopidogrel, and Placebo: A Systematic Review and Meta-Analysis
por: Guan, Baoyi, et al.
Publicado: (2022)

Thrombogenicity and endothelial progenitor cells function during Acute myocardial infarction - comparison of Prasugrel versus Ticagrelor
por: Wiessman, Maya, et al.
Publicado: (2023)

Commentary: Ticagrelor monotherapy—Not for CABG?
por: Sandner, Sigrid, et al.
Publicado: (2022)

Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial
por: Steppich, Birgit, et al.
Publicado: (2017)

De-escalation therapy after acute coronary syndrome: is it reasonable to switch from prasugrel (or ticagrelor) to clopidogrel early?
por: Masiero, Giulia, et al.
Publicado: (2020)

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017
por: Rezaei, Safoura Sheikh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1lqhr9kp4mkngeujdat1cqaaq7